

Contact: Christine Stroup
Kovak-Likly Communications
(203) 762-8833 or
CStroup@KLCpr.com

FOR IMMEDIATE RELEASE

WIN A \$10,000 EDUCATION FUND FOR YOUR MIRACLE CHILD

**Ferring Pharmaceuticals Announces
2007 My Little Miracle Essay Contest**

SUFFERN, NY – February 26, 2007 - If you are a parent who has successfully given birth using Ferring Pharmaceuticals' fertility products, you can win a \$10,000 education fund or one of 11 other prizes to support your child's future. To be eligible, all you need to do is write a brief essay on your journey to achieve parenthood and its impact on your life.

Ferring's My Little Miracle Essay Contest is open to women who have been successfully treated with BRAVELLE[®] (urofollitropin for injection, purified) or MENOPUR[®] (menotropins for injection, USP) or a combination of these medications. The contest celebrates the miracle of birth for parents who have faced infertility, and continues Ferring's tradition of supporting patients by offering education funds for the winners' children.

Ferring is also awarding a \$2,500 education fund to the runner up and \$500 each to 10 honorable mention winners. Since announcing the first contest in 2004, Ferring has awarded \$67,500 in education funds.

Essays should not exceed 1,000 words. They must be written in English, include the entrant's name, address, phone number and age, as well as the child(ren)'s name and age(s), and be submitted with a contest application and labeled digital photo. Entries must be postmarked by July 31, 2007. Winners will be announced at the 63rd Annual Meeting of the American Society for Reproductive Medicine (ASRM), October 13-17, 2007.

For more details and a contest application visit www.ferringfertility.com or www.ferringusa.com or call (203) 762-8833 and ask for the My Little Miracle Essay Contest representative.

-more-

BRAVELLE[®] and MENOPUR[®], like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (incidence of 6.0% and 3.8%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

The treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with BRAVELLE[®] and/or MENOPUR[®] may result in multiple gestations.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, markets BRAVELLE[®], MENOPUR[®], REPRONEX[®] and NOVAREL[®] (chorionic gonadotropin for injection, USP) in the U.S. to infertility specialists and their patients. Ferring also offers the Q-CAP[™], the first and only needle-free reconstitution device, for use with its fertility treatments.

Ferring's line of orthopaedic and urology products includes EUFLEXXA[™], hyaluronic acid for pain from osteoarthritis in the knee. Other products include ACTHREL[®] (corticotropin ovine triflutate for injection) for the differential diagnosis of Cushing's syndrome and DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis.

The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 888-337-7464 or visit www.ferringusa.com or www.ferringfertility.com.

###

Please contact Christine Stroup for full prescribing information.